| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates
|
Strauss, T.
|
|
2017
|
67 |
C |
p. 14-17
4 p.
|
artikel
|
| 2 |
Anticoagulation in children: Making the most of little patients and little evidence
|
Young, Guy
|
|
2017
|
67 |
C |
p. 48-53
6 p.
|
artikel
|
| 3 |
Anticoagulation therapy in neonates, children and adolescents
|
Hepponstall, Michele
|
|
2017
|
67 |
C |
p. 41-47
7 p.
|
artikel
|
| 4 |
Application of genomics for transfusion therapy in sickle cell anemia
|
Chou, Stella T.
|
|
2017
|
67 |
C |
p. 148-154
7 p.
|
artikel
|
| 5 |
Applications of cardiac magnetic resonance imaging in sickle cell disease
|
Niss, Omar
|
|
2017
|
67 |
C |
p. 126-134
9 p.
|
artikel
|
| 6 |
Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies
|
Bauer, Daniel E.
|
|
2017
|
67 |
C |
p. 155-168
14 p.
|
artikel
|
| 7 |
Developmental hemostasis: A lifespan from neonates and pregnancy to the young and elderly adult in a European white population
|
Nowak-Göttl, Ulrike
|
|
2017
|
67 |
C |
p. 2-13
12 p.
|
artikel
|
| 8 |
Diagnosis and treatment of antiphospholipid syndrome in childhood: A review
|
Rumsey, Dax G.
|
|
2017
|
67 |
C |
p. 34-40
7 p.
|
artikel
|
| 9 |
Editorial Board
|
|
|
2017
|
67 |
C |
p. IFC-
1 p.
|
artikel
|
| 10 |
Editorial for special pediatric hemostasis issue BCMD
|
Kenet, G.
|
|
2017
|
67 |
C |
p. 1-
1 p.
|
artikel
|
| 11 |
Health-related quality of life in children, adolescents and adults with hereditary and acquired bleeding disorders
|
Nowak-Göttl, Ulrike
|
|
2017
|
67 |
C |
p. 96-101
6 p.
|
artikel
|
| 12 |
Hydroxyurea: Analytical techniques and quantitative analysis
|
Marahatta, Anu
|
|
2017
|
67 |
C |
p. 135-142
8 p.
|
artikel
|
| 13 |
Novel in vivo and in vitro techniques to image and model the cerebral vasculature in sickle cell disease
|
Buckley, Erin M.
|
|
2017
|
67 |
C |
p. 114-119
6 p.
|
artikel
|
| 14 |
Novel mutation in two brothers with Hermansky Pudlak syndrome type 3
|
Sandrock-Lang, Kirstin
|
|
2017
|
67 |
C |
p. 75-80
6 p.
|
artikel
|
| 15 |
Opportunities for model-based precision dosing in the treatment of sickle cell anemia
|
Dong, Min
|
|
2017
|
67 |
C |
p. 143-147
5 p.
|
artikel
|
| 16 |
Patients with Bernard-Soulier syndrome and different severity of the bleeding phenotype
|
Boeckelmann, D
|
|
2017
|
67 |
C |
p. 69-74
6 p.
|
artikel
|
| 17 |
Pediatric arterial ischemic stroke: Epidemiology, risk factors, and management
|
Felling, Ryan J.
|
|
2017
|
67 |
C |
p. 23-33
11 p.
|
artikel
|
| 18 |
Perioperative management of hemostasis in children and adolescents
|
Bidlingmaier, Christoph
|
|
2017
|
67 |
C |
p. 91-95
5 p.
|
artikel
|
| 19 |
Primary prophylaxis for children with severe congenital factor VII deficiency — Clinical and laboratory assessment
|
Kuperman, AA
|
|
2017
|
67 |
C |
p. 86-90
5 p.
|
artikel
|
| 20 |
Primary prophylaxis in haemophilia care: Guideline update 2016
|
Fischer, Kathelijn
|
|
2017
|
67 |
C |
p. 81-85
5 p.
|
artikel
|
| 21 |
Quantitation of bleeding symptoms in a national registry of patients with inherited platelet disorders
|
Revel-Vilk, Shoshana
|
|
2017
|
67 |
C |
p. 59-62
4 p.
|
artikel
|
| 22 |
Rare bleeding disorders-old diseases in the era of novel options for therapy
|
Livnat, Tami
|
|
2017
|
67 |
C |
p. 63-68
6 p.
|
artikel
|
| 23 |
Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents – What did we learn within the last 20years?
|
Kenet, Gili
|
|
2017
|
67 |
C |
p. 18-22
5 p.
|
artikel
|
| 24 |
Technological Advances in Sickle Cell Disease
|
Ware, Russell E.
|
|
2017
|
67 |
C |
p. 102-103
2 p.
|
artikel
|
| 25 |
The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies
|
McGann, Patrick T.
|
|
2017
|
67 |
C |
p. 104-113
10 p.
|
artikel
|
| 26 |
The use of MRI to monitor iron overload in SCD
|
Wood, John C.
|
|
2017
|
67 |
C |
p. 120-125
6 p.
|
artikel
|
| 27 |
The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years
|
Nowak-Göttl, U.
|
|
2017
|
67 |
C |
p. 54-58
5 p.
|
artikel
|
Tijdschrift beschrijving